OBJECTIVE: Treatments may be more effective in some patients than others, and individual participant data (IPD) meta-analysis of randomized trials provides perhaps the best method of investigating treatment-covariate interactions. Various methods are used; we provide a comprehensive critique and develop guidance on method selection. STUDY DESIGN AND SETTING: We searched MEDLINE to identify all frequentist methods and appraised them for simplicity, risk of bias, and power. IPD data sets were reanalyzed. RESULTS: Four methodological categories were identified: PWT: pooling of within-trial covariate interactions; OSM: "one-stage" model with a treatment-covariate interaction term; TDCS: testing for difference between covariate subgroups in their pooled treatment effects; and CWA: combining PWT with meta-regression. Distinguishing across- and within-trial information is important, as the former may be subject to ecological bias. A strategy is proposed for method selection in different circumstances; PWT or CWA are natural first steps. The OSM method allows for more complex analyses; TDCS should be avoided. Our reanalysis shows that different methods can lead to substantively different findings. CONCLUSION: The choice of method for investigating interactions in IPD meta-analysis is driven mainly by whether across-trial information is considered for inclusion, a decision, which depends on balancing possible improvement in power with an increased risk of bias.
OBJECTIVE: Treatments may be more effective in some patients than others, and individual participant data (IPD) meta-analysis of randomized trials provides perhaps the best method of investigating treatment-covariate interactions. Various methods are used; we provide a comprehensive critique and develop guidance on method selection. STUDY DESIGN AND SETTING: We searched MEDLINE to identify all frequentist methods and appraised them for simplicity, risk of bias, and power. IPD data sets were reanalyzed. RESULTS: Four methodological categories were identified: PWT: pooling of within-trial covariate interactions; OSM: "one-stage" model with a treatment-covariate interaction term; TDCS: testing for difference between covariate subgroups in their pooled treatment effects; and CWA: combining PWT with meta-regression. Distinguishing across- and within-trial information is important, as the former may be subject to ecological bias. A strategy is proposed for method selection in different circumstances; PWT or CWA are natural first steps. The OSM method allows for more complex analyses; TDCS should be avoided. Our reanalysis shows that different methods can lead to substantively different findings. CONCLUSION: The choice of method for investigating interactions in IPD meta-analysis is driven mainly by whether across-trial information is considered for inclusion, a decision, which depends on balancing possible improvement in power with an increased risk of bias.
Authors: Myura Nagendran; Daniel F McAuley; Peter S Kruger; Laurent Papazian; Jonathon D Truwit; John G Laffey; B Taylor Thompson; Mike Clarke; Anthony C Gordon Journal: Intensive Care Med Date: 2016-12-21 Impact factor: 17.440
Authors: Randall Juras; Emily Tanner-Smith; Meredith Kelsey; Mark Lipsey; Jean Layzer Journal: Am J Public Health Date: 2019-02-21 Impact factor: 9.308
Authors: Audrey Mauguen; Cécile Le Péchoux; Michele I Saunders; Steven E Schild; Andrew T Turrisi; Michael Baumann; William T Sause; David Ball; Chandra P Belani; James A Bonner; Aleksander Zajusz; Suzanne E Dahlberg; Matthew Nankivell; Sumithra J Mandrekar; Rebecca Paulus; Katarzyna Behrendt; Rainer Koch; James F Bishop; Stanley Dische; Rodrigo Arriagada; Dirk De Ruysscher; Jean-Pierre Pignon Journal: J Clin Oncol Date: 2012-07-02 Impact factor: 44.544
Authors: Myura Nagendran; James A Russell; Keith R Walley; Stephen J Brett; Gavin D Perkins; Ludhmila Hajjar; Alexina J Mason; Deborah Ashby; Anthony C Gordon Journal: Intensive Care Med Date: 2019-05-06 Impact factor: 17.440
Authors: D Arnold; B Lueza; J-Y Douillard; M Peeters; H-J Lenz; A Venook; V Heinemann; E Van Cutsem; J-P Pignon; J Tabernero; A Cervantes; F Ciardiello Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976